We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?
Read MoreHide Full Article
Key Takeaways
Bristol Myers' Opdivo growth is fueled by new launches, label expansions, and solid global uptake.
EC approved subcutaneous Opdivo and Opdivo Qvantig, boosting momentum across multiple tumor types.
BMY trades at 7.60x forward earnings, below industry peers, as EPS estimates trend upward for 2025-2026.
Bristol Myers ((BMY - Free Report) ) has a strong oncology portfolio comprising blockbuster immune-oncology drug Opdivo, OpdivoQvantig, and Yervoy, among others.
Opdivo is a key drug in BMY’s Growth Portfolio that is approved for several oncology indications. Consistent label expansion of the drug has enabled it to maintain momentum.
Opdivo sales in the United States are being driven by a strong launch in MSI-high colorectal cancer and continued growth in first-line non-small cell lung cancer, while sales outside the country are being bolstered by volume growth.
In May 2025, the European Commission (“EC”) approved the subcutaneous formulation of Opdivo (nivolumab) across multiple solid tumor indications. The EC had earlier approved a perioperative regimen of neoadjuvant Opdivo and chemotherapy followed by adjuvant Opdivo for resectable, high-risk non-small cell lung cancer with PD-L1 Expression ≥1%.
The regulatory body also granted approval to Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use. The initial uptake has been strong and the launch is going well in the United States across all indicated tumor types. Opdivo Qvantig received a permanent J-Code on July 1, which will support additional conversion as reimbursement improves.
The company now expects global Opdivo sales, together with Qvantig, to grow in the mid to high single-digit range in 2025, driven by strong performance in the first half.
BMY depends on the label expansion of approved drugs and approval of new drugs to stabilize its revenue base, as its legacy drugs (Revlimid, Pomalyst, Sprycel and Abraxane) face generic competition.
Competition for BMY’s Oncology Drugs
While the label expansion of Opdivo is positive, the immuno-oncology space is dominated by pharma giant Merck’s ((MRK - Free Report) ) blockbuster drug Keytruda (pembrolizumab), along with Roche’s ((RHHBY - Free Report) ) Tecentriq.
Keytruda is approved for several types of cancer and alone accounts for around 50% of MRK’s pharmaceutical sales. Merck is currently working on different strategies to drive long-term growth of Keytruda.
Roche’s immuno-oncology Tecentriq is also approved for various oncology indications — early-stage (adjuvant) NSCLC, small cell lung cancer, hepatocellular carcinoma and breast cancer, among others. In addition to intravenous infusion, Roche has also obtained approval for Tecentriq as a subcutaneous injection.
BMY’s Price Performance, Valuation and Estimates
Shares of Bristol Myers have lost 13.6% year to date against the industry’s growth of 4.3%.
Image Source: Zacks Investment Research
From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, BMY’s shares currently trade at 7.60X forward earnings, lower than its mean of 8.47X and the large-cap pharma industry’s 14.78X.
Image Source: Zacks Investment Research
The bottom-line estimate for 2025 has moved up to $6.50 from $6.41 in the past 30 days, while that for 2026 has moved south to $6.07 from $6.08 in the same timeframe.
Image: Shutterstock
Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?
Key Takeaways
Bristol Myers ((BMY - Free Report) ) has a strong oncology portfolio comprising blockbuster immune-oncology drug Opdivo, Opdivo Qvantig, and Yervoy, among others.
Opdivo is a key drug in BMY’s Growth Portfolio that is approved for several oncology indications. Consistent label expansion of the drug has enabled it to maintain momentum.
Opdivo sales in the United States are being driven by a strong launch in MSI-high colorectal cancer and continued growth in first-line non-small cell lung cancer, while sales outside the country are being bolstered by volume growth.
In May 2025, the European Commission (“EC”) approved the subcutaneous formulation of Opdivo (nivolumab) across multiple solid tumor indications. The EC had earlier approved a perioperative regimen of neoadjuvant Opdivo and chemotherapy followed by adjuvant Opdivo for resectable, high-risk non-small cell lung cancer with PD-L1 Expression ≥1%.
The regulatory body also granted approval to Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use. The initial uptake has been strong and the launch is going well in the United States across all indicated tumor types. Opdivo Qvantig received a permanent J-Code on July 1, which will support additional conversion as reimbursement improves.
The company now expects global Opdivo sales, together with Qvantig, to grow in the mid to high single-digit range in 2025, driven by strong performance in the first half.
BMY depends on the label expansion of approved drugs and approval of new drugs to stabilize its revenue base, as its legacy drugs (Revlimid, Pomalyst, Sprycel and Abraxane) face generic competition.
Competition for BMY’s Oncology Drugs
While the label expansion of Opdivo is positive, the immuno-oncology space is dominated by pharma giant Merck’s ((MRK - Free Report) ) blockbuster drug Keytruda (pembrolizumab), along with Roche’s ((RHHBY - Free Report) ) Tecentriq.
Keytruda is approved for several types of cancer and alone accounts for around 50% of MRK’s pharmaceutical sales. Merck is currently working on different strategies to drive long-term growth of Keytruda.
Roche’s immuno-oncology Tecentriq is also approved for various oncology indications — early-stage (adjuvant) NSCLC, small cell lung cancer, hepatocellular carcinoma and breast cancer, among others. In addition to intravenous infusion, Roche has also obtained approval for Tecentriq as a subcutaneous injection.
BMY’s Price Performance, Valuation and Estimates
Shares of Bristol Myers have lost 13.6% year to date against the industry’s growth of 4.3%.
Image Source: Zacks Investment Research
From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, BMY’s shares currently trade at 7.60X forward earnings, lower than its mean of 8.47X and the large-cap pharma industry’s 14.78X.
Image Source: Zacks Investment Research
The bottom-line estimate for 2025 has moved up to $6.50 from $6.41 in the past 30 days, while that for 2026 has moved south to $6.07 from $6.08 in the same timeframe.
Image Source: Zacks Investment Research
BMY currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.